{"filing":{"accession_number":"0001193125-26-359418","cik":"0001658551","ticker":"AMLX","company_name":"Amylyx Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-20","report_date":"2026-08-19","primary_document":"d179247d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526359418/d179247d8k.htm"},"events":[{"id":28983,"run_id":26518,"accession_number":"0001193125-26-359418","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.15,"summary":"This disclosure describes entry into an underwriting agreement for a public offering of 14.09 million shares of common stock at $35.50 per share, generating approximately $471.7 million in net proceeds (or $542.5 million if the option is exercised). While the event is clearly material and involves a definitive agreement under Item 1.01, the core transaction is an equity issuance, not a debt issuance. The taxonomy lacks a specific \"equity_issuance\" or \"public_offering\" category; `debt_issuance` is the closest fit for creation of a direct financial obligation, though it is technically misaligned with the equity nature of this transaction.","company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":31097,"accession_number":"0001193125-26-359418","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.15,"reasoning":"This disclosure describes entry into an underwriting agreement for a public offering of 14.09 million shares of common stock at $35.50 per share, generating approximately $471.7 million in net proceeds (or $542.5 million if the option is exercised). While the event is clearly material and involves a definitive agreement under Item 1.01, the core transaction is an equity issuance, not a debt issuance. The taxonomy lacks a specific \"equity_issuance\" or \"public_offering\" category; `debt_issuance` is the closest fit for creation of a direct financial obligation, though it is technically misaligned with the equity nature of this transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T21:29:41.932822+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31097,"accession_number":"0001193125-26-359418","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.15,"reasoning":"This disclosure describes entry into an underwriting agreement for a public offering of 14.09 million shares of common stock at $35.50 per share, generating approximately $471.7 million in net proceeds (or $542.5 million if the option is exercised). While the event is clearly material and involves a definitive agreement under Item 1.01, the core transaction is an equity issuance, not a debt issuance. The taxonomy lacks a specific \"equity_issuance\" or \"public_offering\" category; `debt_issuance` is the closest fit for creation of a direct financial obligation, though it is technically misaligned with the equity nature of this transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T21:29:41.932822+00:00","company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","filing_date":"2026-08-20"}]}